Dogs with Age-Related Debilitation
Most dogs, regardless of breed, experience some form of age-related debilitation as they get older. Symptoms of age-related debilitation include confusion, anxiety or restlessness, decreased desire to play, and changes in sleep cycle. We are investigating a novel drug (RPh201) that has been found in preliminary studies to restore some of the cognitive and biological effects of aging. RPh201 is a botanical extract isolated from the mastic tree, which grows primarily in dry and rocky areas in Mediterranean Europe.
The objective of this study is to evaluate the safety and preliminary efficacy of RPh201 for Injection in dogs with age-related debilitation when administered once weekly for 16 weeks. This is a placebo-controlled study in which dogs are randomized to receive either RPh201 or placebo. Given the design of the study, a dog is twice more likely to receive RPh201 than to be given a placebo. At the study end visit (week 17), the treatment code will be broken and if a dog has been receiving placebo, the dog will be eligible to receive 16 weeks of treatment with RPh201 at no cost.
Dogs at least eight years old and deemed cognitively or otherwise age-debilitated may be eligible for this study. Upons completion of the study, clients receive a UW Veterinary Care credit. For more information, please contact the UW Veterinary Care Oncology Service at 608-263-7600 or Dr. Kim at email@example.com.